Evidence sheet: liberal transfusion thresholds × overall 180-day neurologic outcome in acute brain injury

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Efficacy comparison and presentation of stored materialWhat are the existing subclaim and parent values for the overall acute-brain-injury question?Required	The selected existing question is improved 180-day neurologic outcome across acute brain injury. Its C grade and note describe positive TRAIN and null HEMOTION findings as conflicting. Subclaim score, status and axes are absent; parent C56, Caution and H/R0/I2/E+/B1 remain parent context. S01 S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Absent subclaim values are not filled with parent scores or axes, and no new grade is created. Existing content review remains incomplete.	Separate the subclaim C grade and note, absent score/status/axes, and parent C56/axes	Proposal: Record separate sources for the overall question and original verdict. No new research, calculation or trial was performed.
2	Partly verified	Full text not readStored summary read	N02 · Efficacy comparison and presentation of stored materialWhich brain-injury populations does TRAIN's overall population include?Required	TRAIN studied anemic acute brain injury including traumatic brain injury, subarachnoid hemorrhage and intracerebral hemorrhage, randomizing 850 participants across 72 ICUs in 22 countries. This is not extended to universal effects across all brain injuries, anemia levels or treatment settings. S01	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Exact stage/severity, age, anemia and eligibility criteria, and baseline characteristics and denominators by injury remain unverified. Existing content review remains incomplete.	Anemia, TBI/SAH/ICH, 22 countries and 72 ICUs, and eligibility scope	Proposal: Link materials on the mixed overall population and eligibility conditions. No new research, calculation or trial was performed.
3	Partly verified	Full text not readStored summary read	N03 · Efficacy comparison and presentation of stored materialWhat historical trial strategy does the 9 versus 7 g/dL comparison represent?Required	TRAIN's 9 versus 7 g/dL thresholds are historical trial conditions. Assigned liberal/restrictive strategies are distinguished from actual transfusion volume/timing and individual suitability; no transfusion, threshold or treatment instructions are created. S01	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Actual threshold adherence, crossover/deviations, blood exposure/timing and concomitant treatment details remain unverified. Existing content review remains incomplete.	Separate assigned thresholds, actual exposure, and baseline/concomitant treatment	Proposal: Link assigned strategies and actual exposure. No new research, calculation or trial was performed.
4	Partly verified	Full text not readStored summary read	N04 · Efficacy comparison and presentation of stored materialWhat is known about allocation and assessment in the open-label randomized design?Required	TRAIN was a multinational open-label randomized trial. Open treatment and masking/measurement of the 180-day neurologic assessor are kept separate; the original H/B1 axes do not establish actual assessor blinding. S01	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Allocation generation/concealment, assessor/patient awareness and assessment conditions remain unverified. Existing content review remains incomplete.	Allocation generation/concealment, open-label status, and 180-day assessment/masking	Proposal: Record separate materials for design and outcome measurement. No new research, calculation or trial was performed.
5	Partly verified	Full text not readStored summary read	N05 · Efficacy comparison and presentation of stored materialHow do the 850 randomized participants differ from the 806 in the primary analysis?Required	The preserved statement says TRAIN included only the 806 participants with observed primary outcomes among 850 randomized. The unfavorable-outcome denominators are 246/393 versus 300/413; no new exclusion counts or rates are calculated. S01	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Reasons for unobserved/excluded outcomes, group follow-up/missingness and original ITT/sensitivity plans remain unverified. Existing content review remains incomplete.	Observed-outcome/completer analysis, group denominators 393/413, and missingness/exclusions	Proposal: Link randomized and observed populations and missingness. No new research, calculation or trial was performed.
6	Partly verified	Full text not readStored summary read	N06 · Efficacy comparison and presentation of stored materialHow was unfavorable GOS-E 1~5 outcome at 180 days defined?Required	TRAIN's endpoint was unfavorable GOS-E 1~5 outcome at 180 days. Descriptions of scale levels, components/death, other functional scales or continuous scores are not added where absent from the summary. S01	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Adjudication/questions, assessment window, scale/component results and original collection details remain unverified. Existing content review remains incomplete.	The scale, 1~5 cutoff, timing/adjudication and original component scope	Proposal: Link the unfavorable-outcome definition and individual functional materials. No new research, calculation or trial was performed.
7	Partly verified	Full text not readStored summary read	N07 · Efficacy comparison and presentation of stored materialWhich groups and analysis population underlie TRAIN's unfavorable-outcome counts and rates?Required	TRAIN's original unfavorable outcomes are preserved as 246/393 (62.6%) with the liberal strategy versus 300/413 (72.6%) with the restrictive strategy. They are not converted into rates among all 850 participants, injury-specific response rates or favorable-outcome rates. S01	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Original group/denominator flow, subgroup events, missingness/censoring and exact assessment timing remain unverified. Existing content review remains incomplete.	Original group labels and denominators for 246/393 (62.6%) and 300/413 (72.6%)	Proposal: Document event/person and overall/subgroup denominators. No new research, calculation or trial was performed.
8	Partly verified	Full text not readStored summary read	N08 · Efficacy comparison and presentation of stored materialWhat are the interval, direction and analysis specifications for adjusted RR .86?Required	TRAIN's adjusted RR .86 (95% CI .79~.94), P=.002 is recorded in the original unfavorable-outcome comparison direction. It is not changed into a favorable-outcome RR, individual prediction or effect of transfusion exposure alone; no reciprocal or new effect is calculated. S01	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Covariates, model/assumptions, missing-data handling and exact contrast/population remain unverified. Existing content review remains incomplete.	Unfavorable-outcome RR/CI/P, adjustment and distinction from absolute effects	Proposal: Link comparison direction and adjusted estimates. No new research, calculation or trial was performed.
9	Partly verified	Full text not readStored summary read	N09 · Efficacy comparison and presentation of stored materialHow do TRAIN's absolute difference of −10%p and RR differ?Required	TRAIN's original absolute difference −10.0%p (95% CI −16.5~−3.6) and adjusted RR .86 are different estimates. No new difference is calculated from 62.6/72.6, and the sign is not changed to match HEMOTION's positive-difference coding. S01	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. The exact absolute-difference contrast/adjustment, denominators, covariates and original tables remain unverified. Existing content review remains incomplete.	Original absolute difference −10.0 (−16.5~−3.6), RR, scales and directions	Proposal: Record the sign and interval specifications for each estimate. No new research, calculation or trial was performed.
10	Partly verified	Full text not readStored summary read	N10 · Efficacy comparison and presentation of stored materialWhat is known about primary timing/outcome, prespecified analysis and multiplicity?Required	TRAIN's original primary endpoint was unfavorable GOS-E outcome at 180 days, analyzed in 806 with observed outcomes. Injury-specific, safety and other-timepoint results are not promoted to new primary endpoints or independent confirmation. S01	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Protocol/SAP, prespecified multiplicity/subgroup/missingness plans and amendment history remain unverified. Existing content review remains incomplete.	The 180-day primary outcome, prespecified plan, and subgroup/safety hierarchy	Proposal: Link plans for primary, secondary and subgroup analyses. No new research, calculation or trial was performed.
11	Partly verified	Full text not readStored summary read	N11 · Efficacy comparison and presentation of stored materialWhat exposure information is represented by median transfusion volume of 2 versus 0 units?Required	TRAIN's original median transfusion volume of 2 versus 0 units is preserved. The median is not repurposed as every individual's exposure, total transfusion volume or a dose-response effect. S01	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Timing, analysis population, distribution/blood types, crossover/additional transfusion and concomitant treatment remain unverified. Existing content review remains incomplete.	Separate actual transfusion volume, assigned strategy, distribution/denominator/time	Proposal: Link assigned strategies and actual blood exposure. No new research, calculation or trial was performed.
12	Partly verified	Full text not readStored summary read	N12 · Efficacy comparison and presentation of stored materialDid HEMOTION test the same question as TRAIN's overall population?Required	HEMOTION included traumatic brain injury only and compared 10 versus 7 g/dL; TRAIN included TBI/SAH/ICH and compared 9 versus 7. The populations and liberal thresholds are not treated as identical, and HEMOTION is not transferred as direct replication in SAH/ICH. S01 S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Exact eligibility/severity, baseline characteristics, treatment/exposure and comparability by injury remain unverified. Existing content review remains incomplete.	Traumatic injury only and thresholds of 10 versus 7, versus mixed injuries and 9 versus 7	Proposal: Record population/threshold differences and their relationship to results. No new research, calculation or trial was performed.
13	Partly verified	Full text not readStored summary read	N13 · Efficacy comparison and presentation of stored materialWhat do HEMOTION's 742 randomized and 722 analyzed participants represent?Required	HEMOTION's 742 randomized and 722 analyzed participants are preserved. Its 68.4% versus 73.5% rates are not transferred to all 742 participants or TRAIN's 393/413 denominators; no new exclusion counts or rates are calculated. S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Group analysis denominators, follow-up/missingness/exclusions and sensitivity/ITT plans remain unverified. Existing content review remains incomplete.	Randomized/analysis denominators, group-level missingness and actual outcomes	Proposal: Link randomized/analysis populations and outcome denominators. No new research, calculation or trial was performed.
14	Partly verified	Full text not readStored summary read	N14 · Efficacy comparison and presentation of stored materialWhat do HEMOTION's unfavorable outcomes, adjusted difference and CI estimate?Required	HEMOTION's original 68.4% versus 73.5%, adjusted absolute difference 5.4%p (95% CI −2.9~13.7) and null-result wording are preserved. No new difference, CI or RR is calculated from the rates, and nonsignificance is not changed into equivalence, zero effect or exclusion of important effects. S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Exact group/coding of the adjusted difference, model, original P value, denominators and important-difference threshold remain unverified. Existing content review remains incomplete.	68.4/73.5%, adjusted 5.4%p (−2.9~13.7), and the original null-result wording	Proposal: Document original intervals and estimation specifications. No new research, calculation or trial was performed.
15	Partly verified	Full text not readStored summary read	N15 · Efficacy comparison and presentation of stored materialAre assessment and GOS-E definitions identical at 180 days and six months?Required	TRAIN is preserved as 180-day GOS-E 1~5 and HEMOTION as six-month unfavorable GOS-E outcome. HEMOTION's exact cutoff/adjudication rules and assessment window are not filled with TRAIN's definition. S01 S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Both assessment windows/collection, HEMOTION's unfavorable-outcome definition and baseline-specific classification/weighting remain unverified. Existing content review remains incomplete.	TRAIN's 180-day 1~5 definition and HEMOTION's actual six-month definition/assessment window	Proposal: Compare timing and scale specifications. No new research, calculation or trial was performed.
16	Partly verified	Full text not readStored summary read	N16 · Efficacy comparison and presentation of stored materialHow does the original positive/null conflict wording relate to the numbers?Required	The original account describes TRAIN as positive and HEMOTION as null/opposing, and the subclaim C note describes conflict. Original rates, estimates and CIs are recorded together; the wording alone does not newly establish opposite effect signs or a proven difference under identical conditions. S01 S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. The cause of conflict, direct between-trial interaction, comparability and important-effect threshold remain unverified. Existing content review remains incomplete.	Preserve original verdict/conflict wording alongside each rate, effect and interval	Proposal: Link original conclusion wording and quantitative results separately. No new research, calculation or trial was performed.
17	Partly verified	Full text not readStored summary read	N17 · Efficacy comparison and presentation of stored materialHow are the original Korean/English descriptions of trial size and conclusions preserved?Required	The Korean core summary's original 'larger contemporaneous HEMOTION' wording and the English description of a contemporaneous large trial remain in the full preserved source. Original 850/806 and 742/722 counts are used separately; that wording is not adopted as a new trial-size comparison/verdict fact, and the original is not corrected. S01 S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. New original-text review or correction of the wording/numeric context was not performed here. Existing content review remains incomplete.	History of the original 'larger contemporaneous' wording, actual 850/742 counts and English account	Proposal: Record version-specific sources for original wording and numbers. No new research, calculation or trial was performed.
18	Partly verified	Full text not readStored summary read	N18 · Efficacy comparison and presentation of stored materialDo population/threshold differences explain the cause of the conflict?Required	The original counterview says populations and liberal thresholds differ, but these differences alone cannot explain the opposing conclusions and the cause is unknown. Differences are not newly confirmed as proven effect modification or causes. S01 S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Prespecified interactions, standardized comparisons, covariates/exposure and causal analyses remain unverified. Existing content review remains incomplete.	Differences in 9/10 versus 7 thresholds and mixed/traumatic populations, with cause unverified	Proposal: Record the unverified relationship between condition differences and causes of conflict. No new research, calculation or trial was performed.
19	Unverified	Full text not readStored summary read	N19 · Efficacy comparison and presentation of stored materialCan the overall acute-brain-injury effect be transferred separately to TBI, SAH and ICH?Required	TRAIN's overall result does not certify equal effect size separately in TBI/SAH/ICH. HEMOTION's traumatic-injury result is not transferred to hemorrhage subgroups, and subgroups are not counted as new independent trials. S01 S02	Required information is unverified in the preserved summary. Injury-specific denominators/events, effects/CIs, prespecified subgroups and interactions remain unverified. Existing content review remains incomplete.	Mixed-population overall results, subgroup events/denominators and interaction	Proposal: Record overall/subgroup estimates and conditions separately. No new research, calculation or trial was performed.
20	Partly verified	Full text not readStored summary read	N20 · Efficacy comparison and presentation of stored materialAre trials, questions, timepoints and denominators kept separate when counting?Required	TRAIN and HEMOTION have separate original reports/conditions and their own randomized, analysis and safety denominators and 180-day/six-month outcomes. The parent/current sheet, questions and timepoints are not added as new independent trials or total participants. S01 S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Unique trial, participant and independent-replication totals have not been confirmed and remain unrecorded. Existing content review remains incomplete.	Report/trial/population links, shared denominators/endpoints and unverified unique totals	Proposal: Record study families and shared/duplicate relationships. No new research, calculation or trial was performed.
21	Partly verified	Full text not readStored summary read	N21 · Efficacy comparison and presentation of stored materialWhat are TRAIN's funding, sponsorship and administrative roles?Required	TRAIN's original ESICM NeXT grant, La Fondation des Gueules Cassées, and University Hospital Brussels sponsorship/administrative support are preserved. Public/nonprofit support is not changed into absence of all product/company/staff-author/COI involvement or certification of independence. S01	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Support agreements, product/blood support, authors/contributions, study/analysis/manuscript decision rights and COI remain unverified. Existing content review remains incomplete.	ESICM NeXT, Fondation and Brussels, distinguished from products/staff/COI	Proposal: Document funding and actual roles. No new research, calculation or trial was performed.
22	Partly verified	Full text not readStored summary read	N22 · Efficacy comparison and presentation of stored materialWhat funding scope is covered by HEMOTION's CIHR 'and others' wording?Required	The original HEMOTION record names support from the Canadian Institutes of Health Research and others. Unlisted total funding, in-kind support or company roles are not newly filled in or inherited as verified independence. S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Specific other funding, product support, staff/contributions/author COI and analysis/manuscript roles remain unverified. Existing content review remains incomplete.	Listed funding and 'and others', with products/staff and actual roles unverified	Proposal: Link funding wording and actual support/roles. No new research, calculation or trial was performed.
23	Partly verified	Full text not readStored summary read	N23 · Efficacy comparison and presentation of stored materialWere registration identifiers and actual prespecified plans read?Required	Both original registration identifiers are preserved. Identifiers and historical prespecification accounts are not inherited as registration/plan reading here or as fulfilled endpoint/missingness/subgroup conditions. S01 S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Original registration/amendment history, protocol/SAP and multiplicity/subgroup/missingness plans remain unread. Existing content review remains incomplete.	NCT02968654/03260478 identifiers, protocol/SAP and amendments	Proposal: Link registration versions by report and endpoint. No new research, calculation or trial was performed.
24	Partly verified	Full text not readStored summary read	N24 · Harm-information gaps supplementing the efficacy tableHow do TRAIN's cerebral-ischemia safety denominators differ from the primary outcome?Supplementary	Original cerebral ischemia of 35/397 (8.8%) versus 57/423 (13.5%), RR .65 (95% CI .44~.97), belongs to prespecified serious-adverse-event context. It is not transferred to the 246/393 and 300/413 primary-outcome denominators or overall neurologic improvement. S01	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Safety denominators/collection, cerebral-ischemia definition/adjudication, timing and multiplicity/CI details remain unverified. Existing content review remains incomplete.	Prespecified serious events, 35/397 and 57/423, and separate RR .65/CI specifications	Proposal: Record primary endpoints and cerebral-ischemia events/denominators separately. No new research, calculation or trial was performed.
25	Partly verified	Full text not readStored summary read	N25 · Harm-information gaps supplementing the efficacy tableDo increased transfusion exposure and cerebral-ischemia findings establish overall safety?Supplementary	TRAIN's original median transfusion volume of 2 versus 0 units and cerebral-ischemia results are preserved separately. The no-increase wording for one cerebral-ischemia outcome is not changed into zero transfusion harm, long-term safety or certified individual suitability. S01	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Other safety-event definitions/collection, groups/exposure/denominators, rare/long-term harms and COI details remain unverified. Existing content review remains incomplete.	Blood exposure, individual serious events and rare/long-term harms	Proposal: Link blood exposure and endpoint-specific harms. No new research, calculation or trial was performed.
26	Partly verified	Full text not readStored summary read	N26 · Efficacy comparison and presentation of stored materialCan 180-day unfavorable outcomes be extended to lifelong function or other patients/thresholds?Required	The original materials cover each trial's 180-day/six-month outcomes. They do not create recommendations on lifelong function/mortality, other brain injuries/anemia/exposures, individual thresholds or transfusion selection/administration. S01 S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Long-term follow-up, individual prediction/vulnerable groups and direct evidence for other thresholds/populations remain unverified. Existing content review remains incomplete.	Actual 180-day/six-month assessments, eligibility/exposure and out-of-scope conditions	Proposal: Record evidence gaps by duration, population and exposure. No new research, calculation or trial was performed.
27	Partly verified	Full text not readStored summary read	N27 · Efficacy comparison and presentation of stored materialWhat was actually read in the preserved summaries, URLs and external materials?Required	Both original bibliographic records/URLs and registration identifiers are retained, and the full preserved summary was read for production and marked as summary reading. External papers/plans and COI remain unread; historical review accounts or identifiers do not upgrade reading status. S01 S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. External access, abstract/full-text/registration reading and link/click tests were not performed. Existing content review remains incomplete.	Preserved summaries, TRAIN/HEMOTION URLs/registration and unread external materials	Proposal: Record acquisition, reading and versions by material. No new research, calculation or trial was performed.
28	Partly verified	Full text not readStored summary read	N28 · Efficacy comparison and presentation of stored materialHow are original Korean/English text, verdicts/axes, dates and absent values preserved?Required	The full source's Korean/English text, parent C56/Caution, unrecorded precision/false flags, empty corrections/deliberation, 2026-08-26 and original conflict/cross-check wording are preserved. Subclaim C/note and absent score/status/axes are not filled with parent values. S01 S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. The earlier production record performed no verdict-text translation, clinical full-text review, reassessment, correction or external update. Existing content review remains incomplete.	Subclaim C, parent C56, 2026-08-26, null/false and correction history	Proposal: Link original versions/dates and the selected question. No new research, calculation or trial was performed.
29	Partly verified	Full text not readStored summary read	N29 · Efficacy comparison and presentation of stored materialHow are condition preservation, application and sheet production distinguished from content review?Required	Condition preservation, freezing, application, case production and content review are separate records. Existing content review remains incomplete; counts of rows, reports and materials are not unique clinical-trial or participant totals. S01 S02	Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Existing content review remains incomplete, and original clinical materials have not been newly verified. Existing content review remains incomplete.	Separate condition preservation/freezing/application, case production and incomplete content review	Proposal: Record condition/production versions and user correction history. No new research, calculation or trial was performed.

No items match your search or filter.

29 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-08-26
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: TRAIN's anemic mixed TBI/SAH/ICH population; HEMOTION's traumatic-injury-only population; not extended to effects in every patient or subgroup
Ingredient, formulation and route: Historical assigned strategies of 9 versus 7 g/dL in TRAIN and 10 versus 7 g/dL in HEMOTION; not transfusion, threshold or suitability recommendations
Dose: Not recorded
Comparator: Each trial's liberal/restrictive thresholds and actual transfusion/concomitant treatment; causes of population/threshold differences remain unverified
Measured outcome: TRAIN's unfavorable GOS-E 1~5 at 180 days and HEMOTION's unfavorable outcome at six months; different definitions, denominators and estimates
Duration: Each 180-day/six-month assessment specification; not extended to other durations or lifelong outcomes
Questions outside this scope: Certifying TRAIN's overall result as equal effects across all brain injuries, anemia levels, individuals or each TBI/SAH/ICH subgroup; Repurposing HEMOTION's traumatic-injury 10-versus-7 strategy as identical direct replication of TRAIN's mixed-population 9-versus-7 strategy or hemorrhage subgroups; Calculating new exclusion/missingness counts or rates, total participants or events from 850/806/393/413, 742/722 or safety denominators 397/423; Copying TRAIN's GOS-E 1~5 as HEMOTION's exact cutoff/baseline-specific adjudication, or equating 180-day and six-month windows without verification; Converting original unfavorable-outcome rates into favorable-outcome rates or individual probabilities, or recalculating/reversing signs/reciprocals/new RRs for difference −10.0/RR .86 or difference 5.4/CI; Repurposing original positive/null or opposing-conclusion wording as reversed effect signs, proven interaction under identical conditions, zero HEMOTION effect, equivalence or exclusion of important effects; Presenting population/threshold differences alone as proof of conflict causes or effect modification; Changing original Korean core-summary size wording/English differences into new trial-size judgments or corrections, or deleting current numbers/history; Repurposing transfusion medians of 2/0 as total exposure, every individual's exposure or a new dose-response effect; Changing safety cerebral ischemia of 35/397 versus 57/423 and RR .65/CI into primary-outcome denominators, overall safety, zero other harm or individual suitability; Changing public/nonprofit funding or CIHR 'and others' into absence of all product/company/staff/COI involvement or certified independence; Extending research thresholds, blood exposure or 180-day outcomes into transfusion/threshold/individual-suitability, treatment-administration or replacement guidance; Adding the same reports/trials/populations or different questions/groups/timepoints/denominators as new independent trials or total participants; Inheriting parent scores/axes, historical cross-checks, registration matches or full-text review accounts as subclaim values, current content review or external reading; New search/API use, numerical calculations, hypothetical numbers, new effects/CIs/grades, independent certification or treatment/suitability/administration guidance

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · TRAIN

PubMed

Material type: Multinational open-label randomized trial
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: 62.6% versus 72.6%, adjusted RR 0.86 (0.79~0.94), P=.002. Original absolute difference −10.0%p (CI −16.5~−3.6), adjusted RR and denominators 246/393 versus 300/413 are preserved separately. Safety cerebral-ischemia denominators, transfusion medians and overall/subgroup results are not merged, and no new favorable-outcome rates, differences/CIs or individual effects are calculated.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 TRAIN/PMID39382241 is a 9-versus-7 g/dL strategy trial in a mixed TBI/SAH/ICH population across 72 ICUs in 22 countries, with 850 randomized and 806 analyzed with observed outcomes. Overall results, subgroups and safety denominators 397/423 are distinguished; equal effects across every brain-injury patient/subgroup are not established. The same report/groups/people, timepoints/endpoints and different questions/denominators are not added as new independent trials or participants. Report/material counts are not unique clinical totals; unique trial, participant and independent-replication totals remain unrecorded. S02 HEMOTION/PMID38869931 is a 10-versus-7 g/dL strategy trial in traumatic brain injury only, with 742 randomized and 722 analyzed. It differs from TRAIN's mixed-population 9-versus-7 strategy; the exact six-month GOS-E cutoff/adjudication specification is unverified in this summary. The same report/groups/people, timepoints/endpoints and different questions/denominators are not added as new independent trials or participants. Report/material counts are not unique clinical totals; unique trial, participant and independent-replication totals remain unrecorded.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only the stored JSON summary and bibliography were used for production. This does not constitute external verification or completed content review.
External paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Statistical analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Funding, product-support and COI material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

S02 · HEMOTION

PubMed

Material type: Multinational open-label randomized trial
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: 68.4% versus 73.5%, adjusted absolute difference 5.4%p (95% CI −2.9~13.7), null. Original rates and adjusted difference/interval are preserved separately. Signs are not changed to match TRAIN's absolute-difference coding, and no new RR, difference/CI, between-trial interaction or identical overall/subgroup effect is created.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 TRAIN/PMID39382241 is a 9-versus-7 g/dL strategy trial in a mixed TBI/SAH/ICH population across 72 ICUs in 22 countries, with 850 randomized and 806 analyzed with observed outcomes. Overall results, subgroups and safety denominators 397/423 are distinguished; equal effects across every brain-injury patient/subgroup are not established. The same report/groups/people, timepoints/endpoints and different questions/denominators are not added as new independent trials or participants. Report/material counts are not unique clinical totals; unique trial, participant and independent-replication totals remain unrecorded. S02 HEMOTION/PMID38869931 is a 10-versus-7 g/dL strategy trial in traumatic brain injury only, with 742 randomized and 722 analyzed. It differs from TRAIN's mixed-population 9-versus-7 strategy; the exact six-month GOS-E cutoff/adjudication specification is unverified in this summary. The same report/groups/people, timepoints/endpoints and different questions/denominators are not added as new independent trials or participants. Report/material counts are not unique clinical totals; unique trial, participant and independent-replication totals remain unrecorded.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only the stored JSON summary and bibliography were used for production. This does not constitute external verification or completed content review.
External paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Statistical analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Funding, product-support and COI material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

Report counts versus independent study counts

S01 TRAIN/PMID39382241 is a 9-versus-7 g/dL strategy trial in a mixed TBI/SAH/ICH population across 72 ICUs in 22 countries, with 850 randomized and 806 analyzed with observed outcomes. Overall results, subgroups and safety denominators 397/423 are distinguished; equal effects across every brain-injury patient/subgroup are not established. The same report/groups/people, timepoints/endpoints and different questions/denominators are not added as new independent trials or participants. Report/material counts are not unique clinical totals; unique trial, participant and independent-replication totals remain unrecorded. S02 HEMOTION/PMID38869931 is a 10-versus-7 g/dL strategy trial in traumatic brain injury only, with 742 randomized and 722 analyzed. It differs from TRAIN's mixed-population 9-versus-7 strategy; the exact six-month GOS-E cutoff/adjudication specification is unverified in this summary. The same report/groups/people, timepoints/endpoints and different questions/denominators are not added as new independent trials or participants. Report/material counts are not unique clinical totals; unique trial, participant and independent-replication totals remain unrecorded.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · What are the existing subclaim and parent values for the overall acute-brain-injury question?

Required materials and conditions: Separate the subclaim C grade and note, absent score/status/axes, and parent C56/axes
Conditions for verification: Original materials and analysis scope covering Separate the subclaim C grade and note, absent score/status/axes, and parent C56/axes must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Separate the subclaim C grade and note, absent score/status/axes, and parent C56/axes to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N02 · Which brain-injury populations does TRAIN's overall population include?

Required materials and conditions: Anemia, TBI/SAH/ICH, 22 countries and 72 ICUs, and eligibility scope
Conditions for verification: Original materials and analysis scope covering Anemia, TBI/SAH/ICH, 22 countries and 72 ICUs, and eligibility scope must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Anemia, TBI/SAH/ICH, 22 countries and 72 ICUs, and eligibility scope to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.1; detailed population conditions are Chamgap's own design

N03 · What historical trial strategy does the 9 versus 7 g/dL comparison represent?

Required materials and conditions: Separate assigned thresholds, actual exposure, and baseline/concomitant treatment
Conditions for verification: Original materials and analysis scope covering Separate assigned thresholds, actual exposure, and baseline/concomitant treatment must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Separate assigned thresholds, actual exposure, and baseline/concomitant treatment to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.2–3.2.3; Reverse-direction labels and assessment adaptation are Chamgap design; M03 §3.2.3 and M08 §8.2.2–8.2.3; Chamgap application

N04 · What is known about allocation and assessment in the open-label randomized design?

Required materials and conditions: Allocation generation/concealment, open-label status, and 180-day assessment/masking
Conditions for verification: Original materials and analysis scope covering Allocation generation/concealment, open-label status, and 180-day assessment/masking must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Allocation generation/concealment, open-label status, and 180-day assessment/masking to link the materials needed for the selected question with those currently available.
Referenced methods: M08 §8.1–8.2.3; internal application; M08 Table 8.2.a, M03 §3.2.4; internal application

N05 · How do the 850 randomized participants differ from the 806 in the primary analysis?

Required materials and conditions: Observed-outcome/completer analysis, group denominators 393/413, and missingness/exclusions
Conditions for verification: Original materials and analysis scope covering Observed-outcome/completer analysis, group denominators 393/413, and missingness/exclusions must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Observed-outcome/completer analysis, group denominators 393/413, and missingness/exclusions to link the materials needed for the selected question with those currently available.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

N06 · How was unfavorable GOS-E 1~5 outcome at 180 days defined?

Required materials and conditions: The scale, 1~5 cutoff, timing/adjudication and original component scope
Conditions for verification: Original materials and analysis scope covering The scale, 1~5 cutoff, timing/adjudication and original component scope must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes The scale, 1~5 cutoff, timing/adjudication and original component scope to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptation to each question is internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application; M08 Table 8.2.a, M04 §4.6.3; internal application

N07 · Which groups and analysis population underlie TRAIN's unfavorable-outcome counts and rates?

Required materials and conditions: Original group labels and denominators for 246/393 (62.6%) and 300/413 (72.6%)
Conditions for verification: Original materials and analysis scope covering Original group labels and denominators for 246/393 (62.6%) and 300/413 (72.6%) must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Original group labels and denominators for 246/393 (62.6%) and 300/413 (72.6%) to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are our own design

N08 · What are the interval, direction and analysis specifications for adjusted RR .86?

Required materials and conditions: Unfavorable-outcome RR/CI/P, adjustment and distinction from absolute effects
Conditions for verification: Original materials and analysis scope covering Unfavorable-outcome RR/CI/P, adjustment and distinction from absolute effects must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Unfavorable-outcome RR/CI/P, adjustment and distinction from absolute effects to link the materials needed for the selected question with those currently available.
Referenced methods: M08 §8.2.2, M15 §15.3.1; internal application; M15 §15.3.1–15.3.3; internal application

N09 · How do TRAIN's absolute difference of −10%p and RR differ?

Required materials and conditions: Original absolute difference −10.0 (−16.5~−3.6), RR, scales and directions
Conditions for verification: Original materials and analysis scope covering Original absolute difference −10.0 (−16.5~−3.6), RR, scales and directions must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Original absolute difference −10.0 (−16.5~−3.6), RR, scales and directions to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap's own design; M08 §8.2.2, M15 §15.3.1; Chamgap's own application; M15 §15.3.1–15.3.3; Chamgap's own application

N10 · What is known about primary timing/outcome, prespecified analysis and multiplicity?

Required materials and conditions: The 180-day primary outcome, prespecified plan, and subgroup/safety hierarchy
Conditions for verification: Original materials and analysis scope covering The 180-day primary outcome, prespecified plan, and subgroup/safety hierarchy must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes The 180-day primary outcome, prespecified plan, and subgroup/safety hierarchy to link the materials needed for the selected question with those currently available.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Chamgap's own application

N11 · What exposure information is represented by median transfusion volume of 2 versus 0 units?

Required materials and conditions: Separate actual transfusion volume, assigned strategy, distribution/denominator/time
Conditions for verification: Original materials and analysis scope covering Separate actual transfusion volume, assigned strategy, distribution/denominator/time must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Separate actual transfusion volume, assigned strategy, distribution/denominator/time to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; own application; M03 §3.2.2–3.2.3; reverse-direction labels and test adaptations are our own design

N12 · Did HEMOTION test the same question as TRAIN's overall population?

Required materials and conditions: Traumatic injury only and thresholds of 10 versus 7, versus mixed injuries and 9 versus 7
Conditions for verification: Original materials and analysis scope covering Traumatic injury only and thresholds of 10 versus 7, versus mixed injuries and 9 versus 7 must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Traumatic injury only and thresholds of 10 versus 7, versus mixed injuries and 9 versus 7 to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.1; detailed population conditions are our own design; M03 §3.2.2–3.2.3; reverse-direction labels and test adaptations are our own design; M04 §4.6.1–4.6.2, M15 §15.3.1; own application

N13 · What do HEMOTION's 742 randomized and 722 analyzed participants represent?

Required materials and conditions: Randomized/analysis denominators, group-level missingness and actual outcomes
Conditions for verification: Original materials and analysis scope covering Randomized/analysis denominators, group-level missingness and actual outcomes must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Randomized/analysis denominators, group-level missingness and actual outcomes to link the materials needed for the selected question with those currently available.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

N14 · What do HEMOTION's unfavorable outcomes, adjusted difference and CI estimate?

Required materials and conditions: 68.4/73.5%, adjusted 5.4%p (−2.9~13.7), and the original null-result wording
Conditions for verification: Original materials and analysis scope covering 68.4/73.5%, adjusted 5.4%p (−2.9~13.7), and the original null-result wording must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes 68.4/73.5%, adjusted 5.4%p (−2.9~13.7), and the original null-result wording to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap's own design; M08 §8.2.2, M15 §15.3.1; Chamgap's own application; M15 §15.3.1–15.3.3; Chamgap's own application

N15 · Are assessment and GOS-E definitions identical at 180 days and six months?

Required materials and conditions: TRAIN's 180-day 1~5 definition and HEMOTION's actual six-month definition/assessment window
Conditions for verification: Original materials and analysis scope covering TRAIN's 180-day 1~5 definition and HEMOTION's actual six-month definition/assessment window must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes TRAIN's 180-day 1~5 definition and HEMOTION's actual six-month definition/assessment window to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 Table 8.2.a, M03 §3.2.4; own application; M04 §4.6.1–4.6.2, M15 §15.3.1; own application

N16 · How does the original positive/null conflict wording relate to the numbers?

Required materials and conditions: Preserve original verdict/conflict wording alongside each rate, effect and interval
Conditions for verification: Original materials and analysis scope covering Preserve original verdict/conflict wording alongside each rate, effect and interval must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Preserve original verdict/conflict wording alongside each rate, effect and interval to link the materials needed for the selected question with those currently available.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are our own design; M15 §15.3.1–15.3.3; own application; M04 §4.6.1–4.6.2, M15 §15.3.1; own application

N17 · How are the original Korean/English descriptions of trial size and conclusions preserved?

Required materials and conditions: History of the original 'larger contemporaneous' wording, actual 850/742 counts and English account
Conditions for verification: Original materials and analysis scope covering History of the original 'larger contemporaneous' wording, actual 850/742 counts and English account must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes History of the original 'larger contemporaneous' wording, actual 850/742 counts and English account to link the materials needed for the selected question with those currently available.
Referenced methods: M04 §4.5, §4.6.3; current material-conversion limits reflect review scope and our own design; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are our own design

N18 · Do population/threshold differences explain the cause of the conflict?

Required materials and conditions: Differences in 9/10 versus 7 thresholds and mixed/traumatic populations, with cause unverified
Conditions for verification: Original materials and analysis scope covering Differences in 9/10 versus 7 thresholds and mixed/traumatic populations, with cause unverified must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Differences in 9/10 versus 7 thresholds and mixed/traumatic populations, with cause unverified to link the materials needed for the selected question with those currently available.
Referenced methods: M04 §4.6.1–4.6.2, M15 §15.3.1; own application

N19 · Can the overall acute-brain-injury effect be transferred separately to TBI, SAH and ICH?

Required materials and conditions: Mixed-population overall results, subgroup events/denominators and interaction
Conditions for verification: Original materials and analysis scope covering Mixed-population overall results, subgroup events/denominators and interaction must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Mixed-population overall results, subgroup events/denominators and interaction to link the materials needed for the selected question with those currently available.
Referenced methods: M04 §4.6.1–4.6.2, M15 §15.3.1; own application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are our own design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are our own design

N20 · Are trials, questions, timepoints and denominators kept separate when counting?

Required materials and conditions: Report/trial/population links, shared denominators/endpoints and unverified unique totals
Conditions for verification: Original materials and analysis scope covering Report/trial/population links, shared denominators/endpoints and unverified unique totals must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Report/trial/population links, shared denominators/endpoints and unverified unique totals to link the materials needed for the selected question with those currently available.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

N21 · What are TRAIN's funding, sponsorship and administrative roles?

Required materials and conditions: ESICM NeXT, Fondation and Brussels, distinguished from products/staff/COI
Conditions for verification: Original materials and analysis scope covering ESICM NeXT, Fondation and Brussels, distinguished from products/staff/COI must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes ESICM NeXT, Fondation and Brussels, distinguished from products/staff/COI to link the materials needed for the selected question with those currently available.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

N22 · What funding scope is covered by HEMOTION's CIHR 'and others' wording?

Required materials and conditions: Listed funding and 'and others', with products/staff and actual roles unverified
Conditions for verification: Original materials and analysis scope covering Listed funding and 'and others', with products/staff and actual roles unverified must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Listed funding and 'and others', with products/staff and actual roles unverified to link the materials needed for the selected question with those currently available.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

N23 · Were registration identifiers and actual prespecified plans read?

Required materials and conditions: NCT02968654/03260478 identifiers, protocol/SAP and amendments
Conditions for verification: Original materials and analysis scope covering NCT02968654/03260478 identifiers, protocol/SAP and amendments must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes NCT02968654/03260478 identifiers, protocol/SAP and amendments to link the materials needed for the selected question with those currently available.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

N24 · How do TRAIN's cerebral-ischemia safety denominators differ from the primary outcome?

Required materials and conditions: Prespecified serious events, 35/397 and 57/423, and separate RR .65/CI specifications
Conditions for verification: Original materials and analysis scope covering Prespecified serious events, 35/397 and 57/423, and separate RR .65/CI specifications must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Supplementary
Application exceptions: Address gaps in harm materials for the selected kidney-replacement independence/neurologic outcome. Survival dependence and original mortality/neurologic/safety wording are not used to judge overall safety or create harm rates, treatment-initiation/transfusion/threshold/suitability guidance.
Why this condition is needed: This item distinguishes Prespecified serious events, 35/397 and 57/423, and separate RR .65/CI specifications to link the materials needed for the selected question with those currently available.
Referenced methods: M19 §19.1.2–19.2.4; own application; M19 §19.1.2–19.2.4; detailed distinctions are our own design; M19 §19.1.2–19.2.4; own application; M08 Table 8.2.a, M04 §4.6.3; own application

N25 · Do increased transfusion exposure and cerebral-ischemia findings establish overall safety?

Required materials and conditions: Blood exposure, individual serious events and rare/long-term harms
Conditions for verification: Original materials and analysis scope covering Blood exposure, individual serious events and rare/long-term harms must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Supplementary
Application exceptions: Address gaps in harm materials for the selected kidney-replacement independence/neurologic outcome. Survival dependence and original mortality/neurologic/safety wording are not used to judge overall safety or create harm rates, treatment-initiation/transfusion/threshold/suitability guidance.
Why this condition is needed: This item distinguishes Blood exposure, individual serious events and rare/long-term harms to link the materials needed for the selected question with those currently available.
Referenced methods: M19 §19.1.2–19.2.4; own application; M19 §19.1.2–19.2.4; detailed distinctions are our own design; M19 §19.2 design-specific harm questions; timing details are our own design; M19 §19.1.2–19.2.4; own application; Chamgap's own interpretation boundary. M19 principles are referenced; no official causality tool was run

N26 · Can 180-day unfavorable outcomes be extended to lifelong function or other patients/thresholds?

Required materials and conditions: Actual 180-day/six-month assessments, eligibility/exposure and out-of-scope conditions
Conditions for verification: Original materials and analysis scope covering Actual 180-day/six-month assessments, eligibility/exposure and out-of-scope conditions must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Actual 180-day/six-month assessments, eligibility/exposure and out-of-scope conditions to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.2.1; detailed population conditions are our own design; M03 §3.2.2–3.2.3; reverse-direction labels and test adaptations are our own design; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are our own design

N27 · What was actually read in the preserved summaries, URLs and external materials?

Required materials and conditions: Preserved summaries, TRAIN/HEMOTION URLs/registration and unread external materials
Conditions for verification: Original materials and analysis scope covering Preserved summaries, TRAIN/HEMOTION URLs/registration and unread external materials must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Preserved summaries, TRAIN/HEMOTION URLs/registration and unread external materials to link the materials needed for the selected question with those currently available.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N28 · How are original Korean/English text, verdicts/axes, dates and absent values preserved?

Required materials and conditions: Subclaim C, parent C56, 2026-08-26, null/false and correction history
Conditions for verification: Original materials and analysis scope covering Subclaim C, parent C56, 2026-08-26, null/false and correction history must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Subclaim C, parent C56, 2026-08-26, null/false and correction history to link the materials needed for the selected question with those currently available.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N29 · How are condition preservation, application and sheet production distinguished from content review?

Required materials and conditions: Separate condition preservation/freezing/application, case production and incomplete content review
Conditions for verification: Original materials and analysis scope covering Separate condition preservation/freezing/application, case production and incomplete content review must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes Separate condition preservation/freezing/application, case production and incomplete content review to link the materials needed for the selected question with those currently available.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

What the statuses mean

Met: Status for necessary evidence confirmed after existing content review. No completion is declared in the current presentation.
Partly verified: Some information in the stored summary is linked into the table. External comparison/content review is not complete.
Unverified: The article leaves this unverified, or required material is absent from the current stored summary. This is distinct from zero, absence or safety.
Review incomplete: Existing content review incomplete.
Not reported: Not reported within the stored material actually read; not extended to the entire primary paper.
Inaccessible: Means an actual access failure. Access not attempted here is not assigned this state.
Not applicable: Not used as a substitute for an evidence gap.
Conflicting data: Requires an observed disagreement under the same comparison criteria; not automatically judged in this production.
Insufficient evidence for the conditions: Marks a gap in additional material required by the selected conditions; not a new efficacy grade.

Change history

2026-10-10 · Public page/material version 1.0

Public pages and materials were created from the existing 29 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · What are the existing subclaim and parent values for the overall acute-brain-injury question?

Current findings: The selected existing question is improved 180-day neurologic outcome across acute brain injury. Its C grade and note describe positive TRAIN and null HEMOTION findings as conflicting. Subclaim score, status and axes are absent; parent C56, Caution and H/R0/I2/E+/B1 remain parent context.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Absent subclaim values are not filled with parent scores or axes, and no new grade is created. Existing content review remains incomplete.
Reason for missing information: Absent subclaim values are not filled with parent scores or axes, and no new grade is created.
Required materials and conditions: Separate the subclaim C grade and note, absent score/status/axes, and parent C56/axes
Materials to obtain first: Additional materials for the selected question or user feedback
Further research: Proposal: Record separate sources for the overall question and original verdict. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Separate the subclaim C grade and note, absent score/status/axes, and parent C56/axes must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Separate the subclaim C grade and note, absent score/status/axes, and parent C56/axes to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01 S02

N02 · Which brain-injury populations does TRAIN's overall population include?

Current findings: TRAIN studied anemic acute brain injury including traumatic brain injury, subarachnoid hemorrhage and intracerebral hemorrhage, randomizing 850 participants across 72 ICUs in 22 countries. This is not extended to universal effects across all brain injuries, anemia levels or treatment settings.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Exact stage/severity, age, anemia and eligibility criteria, and baseline characteristics and denominators by injury remain unverified. Existing content review remains incomplete.
Reason for missing information: Exact stage/severity, age, anemia and eligibility criteria, and baseline characteristics and denominators by injury remain unverified.
Required materials and conditions: Anemia, TBI/SAH/ICH, 22 countries and 72 ICUs, and eligibility scope
Materials to obtain first: Eligibility/exclusions, baseline and injury-specific tables, and recruitment materials
Further research: Proposal: Link materials on the mixed overall population and eligibility conditions. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Anemia, TBI/SAH/ICH, 22 countries and 72 ICUs, and eligibility scope must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Anemia, TBI/SAH/ICH, 22 countries and 72 ICUs, and eligibility scope to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.1; detailed population conditions are Chamgap's own design

Related sources S01

N03 · What historical trial strategy does the 9 versus 7 g/dL comparison represent?

Current findings: TRAIN's 9 versus 7 g/dL thresholds are historical trial conditions. Assigned liberal/restrictive strategies are distinguished from actual transfusion volume/timing and individual suitability; no transfusion, threshold or treatment instructions are created.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Actual threshold adherence, crossover/deviations, blood exposure/timing and concomitant treatment details remain unverified. Existing content review remains incomplete.
Reason for missing information: Actual threshold adherence, crossover/deviations, blood exposure/timing and concomitant treatment details remain unverified.
Required materials and conditions: Separate assigned thresholds, actual exposure, and baseline/concomitant treatment
Materials to obtain first: Actual transfusion, adherence and concomitant treatment records, and protocol
Further research: Proposal: Link assigned strategies and actual exposure. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Separate assigned thresholds, actual exposure, and baseline/concomitant treatment must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Separate assigned thresholds, actual exposure, and baseline/concomitant treatment to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.2–3.2.3; Reverse-direction labels and assessment adaptation are Chamgap design; M03 §3.2.3 and M08 §8.2.2–8.2.3; Chamgap application

Related sources S01

N04 · What is known about allocation and assessment in the open-label randomized design?

Current findings: TRAIN was a multinational open-label randomized trial. Open treatment and masking/measurement of the 180-day neurologic assessor are kept separate; the original H/B1 axes do not establish actual assessor blinding.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Allocation generation/concealment, assessor/patient awareness and assessment conditions remain unverified. Existing content review remains incomplete.
Reason for missing information: Allocation generation/concealment, assessor/patient awareness and assessment conditions remain unverified.
Required materials and conditions: Allocation generation/concealment, open-label status, and 180-day assessment/masking
Materials to obtain first: Allocation/assessment guidance, masking and original collection materials
Further research: Proposal: Record separate materials for design and outcome measurement. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Allocation generation/concealment, open-label status, and 180-day assessment/masking must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Allocation generation/concealment, open-label status, and 180-day assessment/masking to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.1–8.2.3; internal application; M08 Table 8.2.a, M03 §3.2.4; internal application

Related sources S01

N05 · How do the 850 randomized participants differ from the 806 in the primary analysis?

Current findings: The preserved statement says TRAIN included only the 806 participants with observed primary outcomes among 850 randomized. The unfavorable-outcome denominators are 246/393 versus 300/413; no new exclusion counts or rates are calculated.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Reasons for unobserved/excluded outcomes, group follow-up/missingness and original ITT/sensitivity plans remain unverified. Existing content review remains incomplete.
Reason for missing information: Reasons for unobserved/excluded outcomes, group follow-up/missingness and original ITT/sensitivity plans remain unverified.
Required materials and conditions: Observed-outcome/completer analysis, group denominators 393/413, and missingness/exclusions
Materials to obtain first: Participant flow, missingness/analysis populations and sensitivity analyses/SAP
Further research: Proposal: Link randomized and observed populations and missingness. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Observed-outcome/completer analysis, group denominators 393/413, and missingness/exclusions must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Observed-outcome/completer analysis, group denominators 393/413, and missingness/exclusions to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

Related sources S01

N06 · How was unfavorable GOS-E 1~5 outcome at 180 days defined?

Current findings: TRAIN's endpoint was unfavorable GOS-E 1~5 outcome at 180 days. Descriptions of scale levels, components/death, other functional scales or continuous scores are not added where absent from the summary.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Adjudication/questions, assessment window, scale/component results and original collection details remain unverified. Existing content review remains incomplete.
Reason for missing information: Adjudication/questions, assessment window, scale/component results and original collection details remain unverified.
Required materials and conditions: The scale, 1~5 cutoff, timing/adjudication and original component scope
Materials to obtain first: GOS-E assessment/endpoint definitions, original outcome tables and prespecified plans
Further research: Proposal: Link the unfavorable-outcome definition and individual functional materials. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering The scale, 1~5 cutoff, timing/adjudication and original component scope must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes The scale, 1~5 cutoff, timing/adjudication and original component scope to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptation to each question is internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application; M08 Table 8.2.a, M04 §4.6.3; internal application

Related sources S01

N07 · Which groups and analysis population underlie TRAIN's unfavorable-outcome counts and rates?

Current findings: TRAIN's original unfavorable outcomes are preserved as 246/393 (62.6%) with the liberal strategy versus 300/413 (72.6%) with the restrictive strategy. They are not converted into rates among all 850 participants, injury-specific response rates or favorable-outcome rates.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Original group/denominator flow, subgroup events, missingness/censoring and exact assessment timing remain unverified. Existing content review remains incomplete.
Reason for missing information: Original group/denominator flow, subgroup events, missingness/censoring and exact assessment timing remain unverified.
Required materials and conditions: Original group labels and denominators for 246/393 (62.6%) and 300/413 (72.6%)
Materials to obtain first: Original outcome/group-denominator tables and subgroup/follow-up tables
Further research: Proposal: Document event/person and overall/subgroup denominators. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Original group labels and denominators for 246/393 (62.6%) and 300/413 (72.6%) must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Original group labels and denominators for 246/393 (62.6%) and 300/413 (72.6%) to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are our own design

Related sources S01

N08 · What are the interval, direction and analysis specifications for adjusted RR .86?

Current findings: TRAIN's adjusted RR .86 (95% CI .79~.94), P=.002 is recorded in the original unfavorable-outcome comparison direction. It is not changed into a favorable-outcome RR, individual prediction or effect of transfusion exposure alone; no reciprocal or new effect is calculated.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Covariates, model/assumptions, missing-data handling and exact contrast/population remain unverified. Existing content review remains incomplete.
Reason for missing information: Covariates, model/assumptions, missing-data handling and exact contrast/population remain unverified.
Required materials and conditions: Unfavorable-outcome RR/CI/P, adjustment and distinction from absolute effects
Materials to obtain first: Adjusted model/SAP and original result/interval tables
Further research: Proposal: Link comparison direction and adjusted estimates. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Unfavorable-outcome RR/CI/P, adjustment and distinction from absolute effects must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Unfavorable-outcome RR/CI/P, adjustment and distinction from absolute effects to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.2.2, M15 §15.3.1; internal application; M15 §15.3.1–15.3.3; internal application

Related sources S01

N09 · How do TRAIN's absolute difference of −10%p and RR differ?

Current findings: TRAIN's original absolute difference −10.0%p (95% CI −16.5~−3.6) and adjusted RR .86 are different estimates. No new difference is calculated from 62.6/72.6, and the sign is not changed to match HEMOTION's positive-difference coding.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. The exact absolute-difference contrast/adjustment, denominators, covariates and original tables remain unverified. Existing content review remains incomplete.
Reason for missing information: The exact absolute-difference contrast/adjustment, denominators, covariates and original tables remain unverified.
Required materials and conditions: Original absolute difference −10.0 (−16.5~−3.6), RR, scales and directions
Materials to obtain first: Original absolute/relative-effect tables and contrast/model definitions
Further research: Proposal: Record the sign and interval specifications for each estimate. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Original absolute difference −10.0 (−16.5~−3.6), RR, scales and directions must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Original absolute difference −10.0 (−16.5~−3.6), RR, scales and directions to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap's own design; M08 §8.2.2, M15 §15.3.1; Chamgap's own application; M15 §15.3.1–15.3.3; Chamgap's own application

Related sources S01

N10 · What is known about primary timing/outcome, prespecified analysis and multiplicity?

Current findings: TRAIN's original primary endpoint was unfavorable GOS-E outcome at 180 days, analyzed in 806 with observed outcomes. Injury-specific, safety and other-timepoint results are not promoted to new primary endpoints or independent confirmation.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Protocol/SAP, prespecified multiplicity/subgroup/missingness plans and amendment history remain unverified. Existing content review remains incomplete.
Reason for missing information: Protocol/SAP, prespecified multiplicity/subgroup/missingness plans and amendment history remain unverified.
Required materials and conditions: The 180-day primary outcome, prespecified plan, and subgroup/safety hierarchy
Materials to obtain first: Registration/protocol/SAP and endpoint hierarchy
Further research: Proposal: Link plans for primary, secondary and subgroup analyses. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering The 180-day primary outcome, prespecified plan, and subgroup/safety hierarchy must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes The 180-day primary outcome, prespecified plan, and subgroup/safety hierarchy to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Chamgap's own application

Related sources S01

N11 · What exposure information is represented by median transfusion volume of 2 versus 0 units?

Current findings: TRAIN's original median transfusion volume of 2 versus 0 units is preserved. The median is not repurposed as every individual's exposure, total transfusion volume or a dose-response effect.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Timing, analysis population, distribution/blood types, crossover/additional transfusion and concomitant treatment remain unverified. Existing content review remains incomplete.
Reason for missing information: Timing, analysis population, distribution/blood types, crossover/additional transfusion and concomitant treatment remain unverified.
Required materials and conditions: Separate actual transfusion volume, assigned strategy, distribution/denominator/time
Materials to obtain first: Actual exposure/distribution, adherence/crossover and concomitant treatment records
Further research: Proposal: Link assigned strategies and actual blood exposure. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Separate actual transfusion volume, assigned strategy, distribution/denominator/time must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Separate actual transfusion volume, assigned strategy, distribution/denominator/time to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; own application; M03 §3.2.2–3.2.3; reverse-direction labels and test adaptations are our own design

Related sources S01

N12 · Did HEMOTION test the same question as TRAIN's overall population?

Current findings: HEMOTION included traumatic brain injury only and compared 10 versus 7 g/dL; TRAIN included TBI/SAH/ICH and compared 9 versus 7. The populations and liberal thresholds are not treated as identical, and HEMOTION is not transferred as direct replication in SAH/ICH.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Exact eligibility/severity, baseline characteristics, treatment/exposure and comparability by injury remain unverified. Existing content review remains incomplete.
Reason for missing information: Exact eligibility/severity, baseline characteristics, treatment/exposure and comparability by injury remain unverified.
Required materials and conditions: Traumatic injury only and thresholds of 10 versus 7, versus mixed injuries and 9 versus 7
Materials to obtain first: Both trials' characteristics/baseline and strategy/exposure tables
Further research: Proposal: Record population/threshold differences and their relationship to results. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Traumatic injury only and thresholds of 10 versus 7, versus mixed injuries and 9 versus 7 must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Traumatic injury only and thresholds of 10 versus 7, versus mixed injuries and 9 versus 7 to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.1; detailed population conditions are our own design; M03 §3.2.2–3.2.3; reverse-direction labels and test adaptations are our own design; M04 §4.6.1–4.6.2, M15 §15.3.1; own application

Related sources S01 S02

N13 · What do HEMOTION's 742 randomized and 722 analyzed participants represent?

Current findings: HEMOTION's 742 randomized and 722 analyzed participants are preserved. Its 68.4% versus 73.5% rates are not transferred to all 742 participants or TRAIN's 393/413 denominators; no new exclusion counts or rates are calculated.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Group analysis denominators, follow-up/missingness/exclusions and sensitivity/ITT plans remain unverified. Existing content review remains incomplete.
Reason for missing information: Group analysis denominators, follow-up/missingness/exclusions and sensitivity/ITT plans remain unverified.
Required materials and conditions: Randomized/analysis denominators, group-level missingness and actual outcomes
Materials to obtain first: HEMOTION flow, original group outcomes/denominators and SAP
Further research: Proposal: Link randomized/analysis populations and outcome denominators. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Randomized/analysis denominators, group-level missingness and actual outcomes must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Randomized/analysis denominators, group-level missingness and actual outcomes to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

Related sources S02

N14 · What do HEMOTION's unfavorable outcomes, adjusted difference and CI estimate?

Current findings: HEMOTION's original 68.4% versus 73.5%, adjusted absolute difference 5.4%p (95% CI −2.9~13.7) and null-result wording are preserved. No new difference, CI or RR is calculated from the rates, and nonsignificance is not changed into equivalence, zero effect or exclusion of important effects.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Exact group/coding of the adjusted difference, model, original P value, denominators and important-difference threshold remain unverified. Existing content review remains incomplete.
Reason for missing information: Exact group/coding of the adjusted difference, model, original P value, denominators and important-difference threshold remain unverified.
Required materials and conditions: 68.4/73.5%, adjusted 5.4%p (−2.9~13.7), and the original null-result wording
Materials to obtain first: HEMOTION original tables, contrast/model and prespecified importance threshold
Further research: Proposal: Document original intervals and estimation specifications. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering 68.4/73.5%, adjusted 5.4%p (−2.9~13.7), and the original null-result wording must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes 68.4/73.5%, adjusted 5.4%p (−2.9~13.7), and the original null-result wording to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap's own design; M08 §8.2.2, M15 §15.3.1; Chamgap's own application; M15 §15.3.1–15.3.3; Chamgap's own application

Related sources S02

N15 · Are assessment and GOS-E definitions identical at 180 days and six months?

Current findings: TRAIN is preserved as 180-day GOS-E 1~5 and HEMOTION as six-month unfavorable GOS-E outcome. HEMOTION's exact cutoff/adjudication rules and assessment window are not filled with TRAIN's definition.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Both assessment windows/collection, HEMOTION's unfavorable-outcome definition and baseline-specific classification/weighting remain unverified. Existing content review remains incomplete.
Reason for missing information: Both assessment windows/collection, HEMOTION's unfavorable-outcome definition and baseline-specific classification/weighting remain unverified.
Required materials and conditions: TRAIN's 180-day 1~5 definition and HEMOTION's actual six-month definition/assessment window
Materials to obtain first: Both trials' endpoint/assessment guidance and prespecified plans
Further research: Proposal: Compare timing and scale specifications. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering TRAIN's 180-day 1~5 definition and HEMOTION's actual six-month definition/assessment window must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes TRAIN's 180-day 1~5 definition and HEMOTION's actual six-month definition/assessment window to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 Table 8.2.a, M03 §3.2.4; own application; M04 §4.6.1–4.6.2, M15 §15.3.1; own application

Related sources S01 S02

N16 · How does the original positive/null conflict wording relate to the numbers?

Current findings: The original account describes TRAIN as positive and HEMOTION as null/opposing, and the subclaim C note describes conflict. Original rates, estimates and CIs are recorded together; the wording alone does not newly establish opposite effect signs or a proven difference under identical conditions.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. The cause of conflict, direct between-trial interaction, comparability and important-effect threshold remain unverified. Existing content review remains incomplete.
Reason for missing information: The cause of conflict, direct between-trial interaction, comparability and important-effect threshold remain unverified.
Required materials and conditions: Preserve original verdict/conflict wording alongside each rate, effect and interval
Materials to obtain first: Both trials' original results/characteristics and prespecified comparison/interaction materials
Further research: Proposal: Link original conclusion wording and quantitative results separately. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Preserve original verdict/conflict wording alongside each rate, effect and interval must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Preserve original verdict/conflict wording alongside each rate, effect and interval to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are our own design; M15 §15.3.1–15.3.3; own application; M04 §4.6.1–4.6.2, M15 §15.3.1; own application

Related sources S01 S02

N17 · How are the original Korean/English descriptions of trial size and conclusions preserved?

Current findings: The Korean core summary's original 'larger contemporaneous HEMOTION' wording and the English description of a contemporaneous large trial remain in the full preserved source. Original 850/806 and 742/722 counts are used separately; that wording is not adopted as a new trial-size comparison/verdict fact, and the original is not corrected.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. New original-text review or correction of the wording/numeric context was not performed here. Existing content review remains incomplete.
Reason for missing information: New original-text review or correction of the wording/numeric context was not performed here.
Required materials and conditions: History of the original 'larger contemporaneous' wording, actual 850/742 counts and English account
Materials to obtain first: Original correction materials or user feedback
Further research: Proposal: Record version-specific sources for original wording and numbers. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering History of the original 'larger contemporaneous' wording, actual 850/742 counts and English account must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes History of the original 'larger contemporaneous' wording, actual 850/742 counts and English account to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5, §4.6.3; current material-conversion limits reflect review scope and our own design; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are our own design

Related sources S01 S02

N18 · Do population/threshold differences explain the cause of the conflict?

Current findings: The original counterview says populations and liberal thresholds differ, but these differences alone cannot explain the opposing conclusions and the cause is unknown. Differences are not newly confirmed as proven effect modification or causes.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Prespecified interactions, standardized comparisons, covariates/exposure and causal analyses remain unverified. Existing content review remains incomplete.
Reason for missing information: Prespecified interactions, standardized comparisons, covariates/exposure and causal analyses remain unverified.
Required materials and conditions: Differences in 9/10 versus 7 thresholds and mixed/traumatic populations, with cause unverified
Materials to obtain first: Trial characteristics, prespecified interactions and comparative analysis materials
Further research: Proposal: Record the unverified relationship between condition differences and causes of conflict. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Differences in 9/10 versus 7 thresholds and mixed/traumatic populations, with cause unverified must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Differences in 9/10 versus 7 thresholds and mixed/traumatic populations, with cause unverified to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.6.1–4.6.2, M15 §15.3.1; own application

Related sources S01 S02

N19 · Can the overall acute-brain-injury effect be transferred separately to TBI, SAH and ICH?

Current findings: TRAIN's overall result does not certify equal effect size separately in TBI/SAH/ICH. HEMOTION's traumatic-injury result is not transferred to hemorrhage subgroups, and subgroups are not counted as new independent trials.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: Required information is unverified in the preserved summary. Injury-specific denominators/events, effects/CIs, prespecified subgroups and interactions remain unverified. Existing content review remains incomplete.
Reason for missing information: Injury-specific denominators/events, effects/CIs, prespecified subgroups and interactions remain unverified.
Required materials and conditions: Mixed-population overall results, subgroup events/denominators and interaction
Materials to obtain first: Injury-specific results, prespecified plans and interaction materials
Further research: Proposal: Record overall/subgroup estimates and conditions separately. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Mixed-population overall results, subgroup events/denominators and interaction must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Mixed-population overall results, subgroup events/denominators and interaction to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.6.1–4.6.2, M15 §15.3.1; own application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are our own design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are our own design

Related sources S01 S02

N20 · Are trials, questions, timepoints and denominators kept separate when counting?

Current findings: TRAIN and HEMOTION have separate original reports/conditions and their own randomized, analysis and safety denominators and 180-day/six-month outcomes. The parent/current sheet, questions and timepoints are not added as new independent trials or total participants.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Unique trial, participant and independent-replication totals have not been confirmed and remain unrecorded. Existing content review remains incomplete.
Reason for missing information: Unique clinical trial, participant and independent replication totals have not been verified and are not recorded.
Required materials and conditions: Report/trial/population links, shared denominators/endpoints and unverified unique totals
Materials to obtain first: Report/trial/population/endpoint linkage materials, if supplied
Further research: Proposal: Record study families and shared/duplicate relationships. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Report/trial/population links, shared denominators/endpoints and unverified unique totals must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Report/trial/population links, shared denominators/endpoints and unverified unique totals to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

Related sources S01 S02

N21 · What are TRAIN's funding, sponsorship and administrative roles?

Current findings: TRAIN's original ESICM NeXT grant, La Fondation des Gueules Cassées, and University Hospital Brussels sponsorship/administrative support are preserved. Public/nonprofit support is not changed into absence of all product/company/staff-author/COI involvement or certification of independence.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Support agreements, product/blood support, authors/contributions, study/analysis/manuscript decision rights and COI remain unverified. Existing content review remains incomplete.
Reason for missing information: Support agreements, product/blood support, authors/contributions, study/analysis/manuscript decision rights and COI remain unverified.
Required materials and conditions: ESICM NeXT, Fondation and Brussels, distinguished from products/staff/COI
Materials to obtain first: Original support/sponsorship roles, contributions/products and author/COI materials
Further research: Proposal: Document funding and actual roles. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering ESICM NeXT, Fondation and Brussels, distinguished from products/staff/COI must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes ESICM NeXT, Fondation and Brussels, distinguished from products/staff/COI to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

Related sources S01

N22 · What funding scope is covered by HEMOTION's CIHR 'and others' wording?

Current findings: The original HEMOTION record names support from the Canadian Institutes of Health Research and others. Unlisted total funding, in-kind support or company roles are not newly filled in or inherited as verified independence.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Specific other funding, product support, staff/contributions/author COI and analysis/manuscript roles remain unverified. Existing content review remains incomplete.
Reason for missing information: Specific other funding, product support, staff/contributions/author COI and analysis/manuscript roles remain unverified.
Required materials and conditions: Listed funding and 'and others', with products/staff and actual roles unverified
Materials to obtain first: Original total-support/in-kind and author/contribution/COI materials
Further research: Proposal: Link funding wording and actual support/roles. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Listed funding and 'and others', with products/staff and actual roles unverified must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Listed funding and 'and others', with products/staff and actual roles unverified to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

Related sources S02

N23 · Were registration identifiers and actual prespecified plans read?

Current findings: Both original registration identifiers are preserved. Identifiers and historical prespecification accounts are not inherited as registration/plan reading here or as fulfilled endpoint/missingness/subgroup conditions.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Original registration/amendment history, protocol/SAP and multiplicity/subgroup/missingness plans remain unread. Existing content review remains incomplete.
Reason for missing information: Original registration/amendment history, protocol/SAP and multiplicity/subgroup/missingness plans remain unread.
Required materials and conditions: NCT02968654/03260478 identifiers, protocol/SAP and amendments
Materials to obtain first: Registration/plan copies or user-supplied materials
Further research: Proposal: Link registration versions by report and endpoint. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering NCT02968654/03260478 identifiers, protocol/SAP and amendments must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes NCT02968654/03260478 identifiers, protocol/SAP and amendments to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

Related sources S01 S02

N24 · How do TRAIN's cerebral-ischemia safety denominators differ from the primary outcome?

Current findings: Original cerebral ischemia of 35/397 (8.8%) versus 57/423 (13.5%), RR .65 (95% CI .44~.97), belongs to prespecified serious-adverse-event context. It is not transferred to the 246/393 and 300/413 primary-outcome denominators or overall neurologic improvement.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Safety denominators/collection, cerebral-ischemia definition/adjudication, timing and multiplicity/CI details remain unverified. Existing content review remains incomplete.
Reason for missing information: Safety denominators/collection, cerebral-ischemia definition/adjudication, timing and multiplicity/CI details remain unverified.
Required materials and conditions: Prespecified serious events, 35/397 and 57/423, and separate RR .65/CI specifications
Materials to obtain first: Safety tables, prespecified plans and event collection/denominators
Further research: Proposal: Record primary endpoints and cerebral-ischemia events/denominators separately. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Prespecified serious events, 35/397 and 57/423, and separate RR .65/CI specifications must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Prespecified serious events, 35/397 and 57/423, and separate RR .65/CI specifications to link the materials needed for the selected question with those currently available.
Application exceptions: Address gaps in harm materials for the selected kidney-replacement independence/neurologic outcome. Survival dependence and original mortality/neurologic/safety wording are not used to judge overall safety or create harm rates, treatment-initiation/transfusion/threshold/suitability guidance.
Referenced methods: M19 §19.1.2–19.2.4; own application; M19 §19.1.2–19.2.4; detailed distinctions are our own design; M19 §19.1.2–19.2.4; own application; M08 Table 8.2.a, M04 §4.6.3; own application

Related sources S01

N25 · Do increased transfusion exposure and cerebral-ischemia findings establish overall safety?

Current findings: TRAIN's original median transfusion volume of 2 versus 0 units and cerebral-ischemia results are preserved separately. The no-increase wording for one cerebral-ischemia outcome is not changed into zero transfusion harm, long-term safety or certified individual suitability.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Other safety-event definitions/collection, groups/exposure/denominators, rare/long-term harms and COI details remain unverified. Existing content review remains incomplete.
Reason for missing information: Other safety-event definitions/collection, groups/exposure/denominators, rare/long-term harms and COI details remain unverified.
Required materials and conditions: Blood exposure, individual serious events and rare/long-term harms
Materials to obtain first: Complete safety tables, actual exposure/follow-up and collection materials
Further research: Proposal: Link blood exposure and endpoint-specific harms. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Blood exposure, individual serious events and rare/long-term harms must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Blood exposure, individual serious events and rare/long-term harms to link the materials needed for the selected question with those currently available.
Application exceptions: Address gaps in harm materials for the selected kidney-replacement independence/neurologic outcome. Survival dependence and original mortality/neurologic/safety wording are not used to judge overall safety or create harm rates, treatment-initiation/transfusion/threshold/suitability guidance.
Referenced methods: M19 §19.1.2–19.2.4; own application; M19 §19.1.2–19.2.4; detailed distinctions are our own design; M19 §19.2 design-specific harm questions; timing details are our own design; M19 §19.1.2–19.2.4; own application; Chamgap's own interpretation boundary. M19 principles are referenced; no official causality tool was run

Related sources S01

N26 · Can 180-day unfavorable outcomes be extended to lifelong function or other patients/thresholds?

Current findings: The original materials cover each trial's 180-day/six-month outcomes. They do not create recommendations on lifelong function/mortality, other brain injuries/anemia/exposures, individual thresholds or transfusion selection/administration.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Long-term follow-up, individual prediction/vulnerable groups and direct evidence for other thresholds/populations remain unverified. Existing content review remains incomplete.
Reason for missing information: Long-term follow-up, individual prediction/vulnerable groups and direct evidence for other thresholds/populations remain unverified.
Required materials and conditions: Actual 180-day/six-month assessments, eligibility/exposure and out-of-scope conditions
Materials to obtain first: Direct long-term or separate-condition materials, if supplied
Further research: Proposal: Record evidence gaps by duration, population and exposure. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Actual 180-day/six-month assessments, eligibility/exposure and out-of-scope conditions must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Actual 180-day/six-month assessments, eligibility/exposure and out-of-scope conditions to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.1; detailed population conditions are our own design; M03 §3.2.2–3.2.3; reverse-direction labels and test adaptations are our own design; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are our own design

Related sources S01 S02

N27 · What was actually read in the preserved summaries, URLs and external materials?

Current findings: Both original bibliographic records/URLs and registration identifiers are retained, and the full preserved summary was read for production and marked as summary reading. External papers/plans and COI remain unread; historical review accounts or identifiers do not upgrade reading status.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. External access, abstract/full-text/registration reading and link/click tests were not performed. Existing content review remains incomplete.
Reason for missing information: External access, abstract/full-text/registration reading and link/click tests were not performed.
Required materials and conditions: Preserved summaries, TRAIN/HEMOTION URLs/registration and unread external materials
Materials to obtain first: User-supplied materials and actual reading records
Further research: Proposal: Record acquisition, reading and versions by material. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Preserved summaries, TRAIN/HEMOTION URLs/registration and unread external materials must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Preserved summaries, TRAIN/HEMOTION URLs/registration and unread external materials to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01 S02

N28 · How are original Korean/English text, verdicts/axes, dates and absent values preserved?

Current findings: The full source's Korean/English text, parent C56/Caution, unrecorded precision/false flags, empty corrections/deliberation, 2026-08-26 and original conflict/cross-check wording are preserved. Subclaim C/note and absent score/status/axes are not filled with parent values.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. The earlier production record performed no verdict-text translation, clinical full-text review, reassessment, correction or external update. Existing content review remains incomplete.
Reason for missing information: The earlier production record performed no verdict-text translation, clinical full-text review, reassessment, correction or external update.
Required materials and conditions: Subclaim C, parent C56, 2026-08-26, null/false and correction history
Materials to obtain first: Original correction materials or user feedback
Further research: Proposal: Link original versions/dates and the selected question. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Subclaim C, parent C56, 2026-08-26, null/false and correction history must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Subclaim C, parent C56, 2026-08-26, null/false and correction history to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01 S02

N29 · How are condition preservation, application and sheet production distinguished from content review?

Current findings: Condition preservation, freezing, application, case production and content review are separate records. Existing content review remains incomplete; counts of rows, reports and materials are not unique clinical-trial or participant totals.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant preserved-summary information is recorded; detailed original materials are unread and existing content review remains incomplete. Existing content review remains incomplete, and original clinical materials have not been newly verified. Existing content review remains incomplete.
Reason for missing information: Review of the existing content is incomplete and clinical source material was not newly verified.
Required materials and conditions: Separate condition preservation/freezing/application, case production and incomplete content review
Materials to obtain first: User review feedback and additional preserved materials
Further research: Proposal: Record condition/production versions and user correction history. No new research, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Original materials and analysis scope covering Separate condition preservation/freezing/application, case production and incomplete content review must be available, with unverified matters distinguished. Preserved statements are linked here; existing content review remains incomplete.
Why this condition is needed: This item distinguishes Separate condition preservation/freezing/application, case production and incomplete content review to link the materials needed for the selected question with those currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01 S02